Industrial Pharmacy Advisory Group

Changes at the RPS Industrial Pharmacy Forum

A new Industrial Pharmacy Advisory Group (IPAG) is replacing this Industrial Pharmacy Forum in 2021.

The group will support the RPS national boards on matters affecting Industrial Pharmacy and Pharmaceutical Science and provide expertise to respond to emerging issues appropriately.

The group will support the ongoing work of the RPS in Industry including the development, implementation and dissemination of professional standards.

We are currently recruiting for a Group Chair and Members - see below.

Call for Industrial Pharmacy Advisory Group Members & Chair

Remuneration: Expenses

Location: Virtual and/or face-to-face meetings will take place in London

RPS is the professional leadership body for pharmacists and pharmacy in England, Scotland and Wales. Our mission is to put pharmacy at the forefront of healthcare; our vision is to become the world leader in the safe and effective use of medicines.

Since the Society was founded in 1841 we have championed the profession and are internationally renowned as publishers of medicines information. Our Royal Charter gives us a unique status in pharmacy.

We promote pharmacy in the media and government, lead the way in medicines information, and support pharmacists in their education and development.

We are recruiting members and for a new Chair for our new Industrial Pharmacy Advisory Group (IPAG) which will replace the Industrial Pharmacy Forum in 2021.

Definition of Industrial Pharmacy

For the purpose of this group, industrial pharmacy includes all roles undertaken by pharmacists and pharmaceutical scientists within the pharmaceutical or allied industries (e.g. med-tech, FCMG, Consultancy) and those with an active interest in industrial pharmacy. 

It also covers areas of practice/ work where industrial pharmacy expertise and influence is required to support the safe and effective use of medicines.

Membership of the group

Membership of the group is based on an individual’s own professional experience rather than them being representative of another group or their organisations. As such the group will be constituted to ensure that individual members have a wide breadth of experience. RPS has ultimate responsibility for the constitution of the group (please refer to the attached Terms of Reference).

Membership is open to Industrial Pharmacists and Pharmaceutical Scientists who are members of the RPS.

Role descriptions and Terms of Reference

For more information on these roles, please see full Member Specification and Terms of Reference. Alternatively, contact the current Chair Sue Kilby at [email protected] or RPS Chief Scientist Professor Gino Martini at [email protected].

How to apply

Submit your CV and a short covering email (max 500 words) expressing your interest and reasons for contributing, to [email protected]

Closing date for applications

31 October 2020.

EIPG Webinar

Advanced Therapy Medicinal Products, with Robert Smith

Tuesday 24 November 2020, 1700 CET (1600 GMT)

Advanced Therapy Medicinal Products (ATMPs) include gene therapy products, somatic cell therapy and products produced from tissue engineering. They offer ground-breaking new opportunities for the treatment of disease and injury.

The webinar will look at the main types of ATMPs and provide an outline of their manufacture and testing. In Europe, the Committee for Advanced Therapies (CAT) plays a central role in the scientific assessment of advanced therapy medicines for humans; the speaker will review the regulations and guidelines applicable to these products.

Find out more

Download webinar flyer

How To Join

Register using this webinar registration form.

Instructions for joining the webinar will be shown after you submit the form.

The EIPG newsletter

Read the official newsletter of the European Industrial Pharmacists' Group.

  • September 2020
  • The latest issue of EIPG's monthly newsletter has an article from AFI’s national delegate and our Vice-President Technical and Professional Development, Piero Iamartino on how AFI's activities have continued during the COVID-19 emergency.
    Earlier in September, at an EIPG–Tecniche Nuove webinar, Dr Francesco Boschi summarised the most relevant comments to the V12 draft document of Annex 1 (appendix of Eudralex Vol. 4 EU GMP) as developed by the EIPG national working groups. Professor Gino Martini, Chief Scientific Officer for the Royal Pharmaceutical Society and former EIPG President was the main speaker at a joint EIPG & EPSA webinar Innovation and the Pharmacist – putting pharmacy at the forefront of healthcare.
    Please send me your report of dissemination by mid-October and, stay safe and protected against COVID-19!
  • July 2020
    EIPG's July newsletter has an article from our colleagues in Belgium. Alexia Rensonent and Thomas Lion, both board members of the Belgian UPIP-VAPI Industrial Pharmacists Association, they tell us about COVID-19's effect on freelance QP and RP-GDP activities.
    You'll also find a short report from EIPG’s first ever digital General Assembly held on 18th of July 2020, through our new communication platform. This year’s General Assembly in Leiden, the Netherlands and hosted by NIA, our Dutch Association, had to be postponed.
    Please send me your dissemination reports by the middle of August 2020, and I wish you all a nice, safe summer!
  • June 2020
    EIPG's monthly newsletter for June has an interesting article on Latvia’s new Medicines reimbursement system and Medicinal Products Register prepared with the valuable contribution of the Pharmacists’ Society of Lavia (LFB) and their President Linda Meška.
    You can also read about the decision of EIPG Bureau to hold a digital General Assembly on 18 July as the General Assembly due to be held in the Netherlands and hosted by our Dutch colleagues of NIA has been postponed due to COVID-19 situation.
    Please forward this issue to your members of your association occupied in pharmaceutical industry and allied companies and confirm your dissemination until 15 July 2020.
  • May 2020
    The May issue of EIPG's monthly newsletter has an interesting article on how COVID-19 has redesigned the job market at a deep level, and what are the skills pharma worforce is expected to possess to face a still uncertain future.
    Analysis is presented from consultancy firms on how CHROs should look at the new scenarios to sustain both business activities and the need for some employees to find a new position.
    Also, Professor Gino Martini, Chief Scientist for the Royal Pharmaceutical Society in Great Britain talks about the latest issues, innovations and developments in the pharmaceutical sciences and research.
    And finally, a look at the still open consultations on Annex 21 and Annex 1.